Latest news with #Saudi-U.S.InvestmentForum2025
Cision Canada
22-05-2025
- Business
- Cision Canada
Cellenkos Inc. and King Faisal Specialist Hospital & Research Centre, Sign Strategic MOU to Advance T Regulatory Cell Therapies for Unmet Diseases
KFSHRC to lead Clinical Trials Targeting Aplastic Anemia and Graft vs. Host Disease Cellenkos to Support Local Cell and Gene Therapy Manufacturing at KFSHRC RIYADH, Saudi Arabia and HOUSTON, May 22, 2025 /CNW/ -- King Faisal Specialist Hospital & Research Centre (KFSHRC) and Cellenkos ® Inc., a Texas based clinical stage biotech company, have signed a strategic international memorandum of understanding (MOU) following the Saudi-U.S. Investment Forum 2025, underscoring KFSHRC's commitment to contributing to the advancement of medical innovation and strengthening strategic global collaborations and Cellenkos' resolve to develop T regulatory (Treg) Cell Therapies for treatment of rare diseases with unmet medical needs. This landmark MOU establishes the foundation for strategic collaboration between KFSHRC and Cellenkos to launch the first clinical trial alliance between the Kingdom of Saudi Arabia and the United States. The partnership will begin with two clinical trials evaluating Cellenkos' Treg products for the treatment of Graft vs. Host Disease (GVHD) and Aplastic Anemia. This initiative will pave the way for expanding into neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS) and cardiovascular disorders. Simultaneously, Cellenkos will assist KFSHRC in building local infrastructure for cell and gene therapy manufacturing, training, and education. "At KFSHRC, we remain deeply committed to improving treatment options for patients with Aplastic Anemia and GVHD—conditions that present serious challenges for many individuals and families in our care. We look forward to working together with Cellenkos in a way that serves our patients and supports the advancement of tailored therapeutic solutions," said His Excellency Dr. Majid bin Ibrahim Al Fayyadh, CEO of KFSHRC. "We are thrilled about this partnership and opportunity to work alongside a world-class institution like KFSHRC," said Dr. Simrit Parmar, Founder of Cellenkos and Faculty at Texas A&M University. "Having seen firsthand the sophistication of KFSHRC's bone marrow transplant program—including locally manufactured CD19 CAR T therapies, we're confident that this collaboration will significantly reduce costs and improve patient access. By utilizing KFSHRC's cord blood bank as a local source for manufacturing, we can optimize scalability and impact. This marks the beginning of a transformative era in Treg cell therapy for global healthcare." About KFSHRC KFSHRC is a leading healthcare, research, and education institution recognized throughout Saudi Arabia and the Middle East. Established in 1975, the hospital is committed to providing world-class medical care and continuously advancing healthcare standards within the Kingdom, the Middle East, and the world. KFSHRC's mission is to serve society with the highest level of healthcare and the best patient experience in an integrated education and research setting. KFSHRC performs more than 300 Bone Marrow/Hematopoietic Stem Cell transplants a year, with 250 allogeneic transplants, where 11% of these transplants are for patients afflicted with Aplastic Anemia; 5% afflicted with Congenital BM Failure Syndromes, and another 12% for other bone marrow failure syndromes. KFSHRC has extensive experience in not only treating patients with advanced cell-based therapies such as CAR T, with 58 treatments in 2024 alone, but also has conducted more than 10 CAR T and Gene Therapy clinical trials, has an on-site CAR-T manufacturing facility, and is building a large GMP Cell and Gene Therapy (CAGT) manufacturing facility on site. Additionally, KFSHRC Cord Blood Bank, launched in 2005, has approximately 3,000 stored cord blood units. King Faisal Specialist Hospital & Research Centre has been ranked #1 in the Middle East and North Africa, and #15 globally among the world's top 250 academic medical centers. It is also recognized as the most valuable healthcare brand in the Middle East according to Brand Finance 2024, and named one of the World's Best Smart Hospitals by Newsweek magazine for 2025. About Cellenkos Inc. Cellenkos is a clinical-stage biotechnology company advancing allogeneic, off-the-shelf, cord blood-derived T regulatory (Treg) cell therapies for rare inflammatory and autoimmune diseases. Cellenkos is a clinical-stage biotechnology company based in Houston, Texas, focused on developing off-the-shelf Treg cell therapies for rare inflammatory diseases and autoimmune disorders. Cellenkos' Treg therapies, derived from allogeneic umbilical cord blood and its proprietary CRANE ® platform enables tissue-directed Treg therapies without HLA or ABO matching, suitable for outpatient administration and rapid point-of-care delivery. The company is committed to advancing the development of these promising therapies to improve the lives of patients with rare and underserved conditions. Media Contacts
Yahoo
22-05-2025
- Business
- Yahoo
Cellenkos Inc. and King Faisal Specialist Hospital & Research Centre, Sign Strategic MOU to Advance T Regulatory Cell Therapies for Unmet Diseases
KFSHRC to lead Clinical Trials Targeting Aplastic Anemia and Graft vs. Host Disease Cellenkos to Support Local Cell and Gene Therapy Manufacturing at KFSHRC RIYADH, Saudi Arabia and HOUSTON, May 22, 2025 /CNW/ -- King Faisal Specialist Hospital & Research Centre (KFSHRC) and Cellenkos® Inc., a Texas based clinical stage biotech company, have signed a strategic international memorandum of understanding (MOU) following the Saudi-U.S. Investment Forum 2025, underscoring KFSHRC's commitment to contributing to the advancement of medical innovation and strengthening strategic global collaborations and Cellenkos' resolve to develop T regulatory (Treg) Cell Therapies for treatment of rare diseases with unmet medical needs. This landmark MOU establishes the foundation for strategic collaboration between KFSHRC and Cellenkos to launch the first clinical trial alliance between the Kingdom of Saudi Arabia and the United States. The partnership will begin with two clinical trials evaluating Cellenkos' Treg products for the treatment of Graft vs. Host Disease (GVHD) and Aplastic Anemia. This initiative will pave the way for expanding into neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS) and cardiovascular disorders. Simultaneously, Cellenkos will assist KFSHRC in building local infrastructure for cell and gene therapy manufacturing, training, and education. "At KFSHRC, we remain deeply committed to improving treatment options for patients with Aplastic Anemia and GVHD—conditions that present serious challenges for many individuals and families in our care. We look forward to working together with Cellenkos in a way that serves our patients and supports the advancement of tailored therapeutic solutions," said His Excellency Dr. Majid bin Ibrahim Al Fayyadh, CEO of KFSHRC. "We are thrilled about this partnership and opportunity to work alongside a world-class institution like KFSHRC," said Dr. Simrit Parmar, Founder of Cellenkos and Faculty at Texas A&M University. "Having seen firsthand the sophistication of KFSHRC's bone marrow transplant program—including locally manufactured CD19 CAR T therapies, we're confident that this collaboration will significantly reduce costs and improve patient access. By utilizing KFSHRC's cord blood bank as a local source for manufacturing, we can optimize scalability and impact. This marks the beginning of a transformative era in Treg cell therapy for global healthcare." About KFSHRC KFSHRC is a leading healthcare, research, and education institution recognized throughout Saudi Arabia and the Middle East. Established in 1975, the hospital is committed to providing world-class medical care and continuously advancing healthcare standards within the Kingdom, the Middle East, and the world. KFSHRC's mission is to serve society with the highest level of healthcare and the best patient experience in an integrated education and research setting. KFSHRC performs more than 300 Bone Marrow/Hematopoietic Stem Cell transplants a year, with 250 allogeneic transplants, where 11% of these transplants are for patients afflicted with Aplastic Anemia; 5% afflicted with Congenital BM Failure Syndromes, and another 12% for other bone marrow failure syndromes. KFSHRC has extensive experience in not only treating patients with advanced cell-based therapies such as CAR T, with 58 treatments in 2024 alone, but also has conducted more than 10 CAR T and Gene Therapy clinical trials, has an on-site CAR-T manufacturing facility, and is building a large GMP Cell and Gene Therapy (CAGT) manufacturing facility on site. Additionally, KFSHRC Cord Blood Bank, launched in 2005, has approximately 3,000 stored cord blood units. King Faisal Specialist Hospital & Research Centre has been ranked #1 in the Middle East and North Africa, and #15 globally among the world's top 250 academic medical centers. It is also recognized as the most valuable healthcare brand in the Middle East according to Brand Finance 2024, and named one of the World's Best Smart Hospitals by Newsweek magazine for 2025. Learn more at: About Cellenkos Inc. Cellenkos is a clinical-stage biotechnology company advancing allogeneic, off-the-shelf, cord blood-derived T regulatory (Treg) cell therapies for rare inflammatory and autoimmune diseases. Cellenkos is a clinical-stage biotechnology company based in Houston, Texas, focused on developing off-the-shelf Treg cell therapies for rare inflammatory diseases and autoimmune disorders. Cellenkos' Treg therapies, derived from allogeneic umbilical cord blood and its proprietary CRANE® platform enables tissue-directed Treg therapies without HLA or ABO matching, suitable for outpatient administration and rapid point-of-care delivery. The company is committed to advancing the development of these promising therapies to improve the lives of patients with rare and underserved conditions. Learn more at: Media Contacts KFSHRC: mediacoverage@ Cellenkos: BD@ View original content to download multimedia: SOURCE Cellenkos, Inc. View original content to download multimedia:
Saudi Gazette
14-05-2025
- Business
- Saudi Gazette
STC Bank partners with Arthur Lawrence for operational outsourcing, job description development services
STC Bank has announced on Monday, on the sidelines of the Saudi-U.S. Investment Forum 2025, an agreement with Arthur Lawrence to deliver operational outsourcing and job description development services to the bank. As part of the agreement, STC Bank will now be supported by Arthur Lawrence in developing and aligning job descriptions for roles across the company to ensure alignment with STC Bank's vision. Arthur Lawrence will also be responsible for delivering required outsourced human resources to the bank. By leveraging its proven methodologies and sector expertise, Arthur Lawrence will help ensure that every role at STC Bank is aligned with the bank's evolving business goals, enhancing operational clarity and enabling smarter workforce planning across all departments. Arthur Lawrence is a U.S.-headquartered professional services firm specializing in technology, talent, and business transformation. With a presence in the Kingdom through its subsidiary Arthur Lawrence Arabia, the firm delivers high-impact consulting and outsourcing solutions tailored to organizational growth and operational efficiency. STC Bank is a licensed digital bank in Saudi Arabia, driven by the growing demand for convenient, accessible, and digital-first banking solutions from the Kingdom's tech-savvy population. The bank was launched as a wallet in 2018 and became a fully licensed digital bank under the Saudi Central Bank (SAMA) in early 2025, and it has steadily grown into a trusted financial partner for a diverse range of users, retail and corporate.
Barnama
13-05-2025
- Business
- Barnama
Trump Begins Visit To Gulf States To Strengthen Ties
A screen displays a picture of Saudi Arabia's King Salman bin Abdulaziz Al-Saud shaking the hand of U.S. President Donald Trump at the Saudi-U.S. Investment Forum 2025 in Ritz Carlton Hotel, ahead of the arrival of the U.S. President, in Riyadh, Saudi Arabia, May 13, 2025. REUTERS/Pesha Magid By Amirudin Ahmad RIYADH, May 13 (Bernama) -- United States (US) President Donald Trump's official visit to several Gulf Arab nations is widely seen as an effort to strengthen strategic relations, particularly in the economic sphere, and to consolidate America's regional security role in the Middle East. Universiti Malaya Foreign Affairs, Security, and Strategy Analyst Collins Chong Yew Keat said the choice of Saudi Arabia as the first destination for Trump's visit after commencing his second term in January sends a clear signal that Riyadh is indispensable to Washington at a time when the US is mired in global geopolitics. bootstrap slideshow Trump, he said, views Saudi Arabia as the key ally in the Middle East that can guarantee a strong investment. "For his second term, Trump needs a strong investment pledge from Saudi. We can see how this Saudi government led by Mohammed bin Salman has pledged to increase investment in the US to US$1 trillion within the next four to five years. 'And so it appears important for Trump to gain a return on the investment pledge or capital from Saudi Arabia and also to ensure a win-win situation for both sides," Chong told Bernama. Chong said that Saudi Arabia should view the visit as a significant opportunity to strengthen bilateral relations and secure strategic support from Washington, including in the area of security. International media reported on Monday that Trump is scheduled to meet with Saudi Arabia's Crown Prince and Prime Minister, Mohammed bin Salman, and to attend meetings with the leaders of the Gulf states and representatives from the technology and business sectors until May 16. Prominent business figures, including Elon Musk, are expected to attend the Saudi-US Investment Forum set to take place in Riyadh on May 13.
Yahoo
12-05-2025
- Business
- Yahoo
Resecurity Contributes to the U.S.-Saudi Investment Forum
RIYADH, Saudi Arabia, May 12, 2025--(BUSINESS WIRE)--Resecurity, a U.S.-based leader in cybersecurity and threat intelligence, is proud to announce its participation in the Saudi-U.S. Investment Forum 2025, taking place on May 13 at the King Abdulaziz International Conference Center in Riyadh. As a Platinum Sponsor of the Special Welcome Reception on the Eve of the Saudi-U.S. Investment Forum, Resecurity supported a high-level engagement hosted in coordination with the U.S.-Saudi Business Council, bringing together senior government and business leaders on the eve of the Forum. The company's participation highlights its commitment to safeguarding digital infrastructure and supporting trusted innovation across borders. "Cybersecurity today is not just a technical issue — it's a cornerstone of economic security and national stability," said Gene Yoo, CEO of Resecurity. "We are honored to support this important forum and continue building trusted partnerships that help defend critical infrastructure and enable secure growth." Resecurity's involvement comes at a time when digital transformation is reshaping economies and critical infrastructure worldwide. The company's intelligence-driven approach to cybersecurity is helping governments and enterprises detect advanced threats, combat cybercrime, and protect sensitive data and operations. A Shared Vision for Secure Innovation The Saudi-U.S. Investment Forum 2025 is being held on the occasion of the state visit of the 45th and 47th President of the United States, Mr. Donald J. Trump. Taking place at the King Abdulaziz International Conference Center in Riyadh on May 13, the Forum celebrates nearly a century of bilateral cooperation and focuses on expanding strategic investments in key sectors. American foreign direct investment (FDI) in Saudi Arabia now totals around $54 billion, representing nearly one in every four dollars of FDI in the Kingdom — with Saudi Arabia also being a significant investor in the United States. As both nations prioritize economic diversification and technological innovation, cybersecurity remains central to protecting shared progress. About Resecurity Resecurity® is a cybersecurity company that delivers a unified endpoint protection, fraud prevention, risk management, and cyber threat intelligence platform. Known for providing best-of-breed data-driven intelligence solutions, Resecurity's services and platforms focus on early-warning identification of data breaches and comprehensive protection against cybersecurity risks. Founded in 2016, it has been globally recognized as one of the world's most innovative cybersecurity companies with the sole mission of enabling organizations to combat cyber threats regardless of how sophisticated they are. Most recently, by Inc. Magazine, Resecurity was named one of the Top 10 fastest-growing private cybersecurity companies in Los Angeles, California. As a member of InfraGard National Members Alliance (INMA), AFCEA, NDIA, SIA, FS-ISAC, and the American Chamber of Commerce in Saudi Arabia (AmChamKSA), Singapore (AmChamSG), Korea (AmChamKorea), Mexico (AmChamMX), Thailand (AmChamThailand), and UAE (AmChamDubai). To learn more about Resecurity, visit View source version on Contacts Gene Yoopress@
